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ABSTRACT
Several reports suggest that a chronic inﬂammatory process plays a key role in coronary artery
plaque instability and subsequent occlusive thrombosis. In a previous study, we found that TLR4
(Toll-like receptor 4) mediates the synthesis of cytokines in circulating monocytes of patients with
AMI (acute myocardial infarction); however, it remains unclear whether TLRs are expressed at
the site of the ruptured plaque in these patients. The aim of the present study was to determine
whether TLR2 and TLR4 are expressed at the site of ruptured plaques in patients with AMI
and to compare this with systemic levels. The study included 62 patients with AMI, 20 patients
with SA (stable angina) and 32 subjects with a normal coronary angiogram (control). Local
samples from the site of the ruptured plaque were taken from patients with AMI using aspiration
catheterization. Systemic blood samples from the aorta were taken from patients with AMI and SA
and controls. Systemic levels of TLR2 and TLR4 were higher in patients with AMI than in patients
with SA and controls. In patients with AMI, local TLR4 levels were higher than systemic levels.
There was no signiﬁcant difference in TLR2 levels between local and systemic samples. TLR4
immunostaining was positive in inﬁltrating macrophages in ruptured plaque material. Cardiac
events were observed in 16 patients with AMI at the time of the 6-month follow-up study. Local
and systemic levels of TLR4 were higher in patients with AMI with cardiac events than in those
without. These results indicate an increase in monocytic TLR4 expression not only in the systemic
circulation, but also at the site of plaque rupture. In conclusion, expression of both systemic and
local plaque TLR4 may be one of the mechanisms responsible for the pathogenesis of AMI.
INTRODUCTION
Clinical and histopathological studies suggest that a
chronic inﬂammatory process plays a key role in coron-
ary artery plaque instability and subsequent occlusive
thrombosis [1,2]. In an autopsy study [3], ruptured and
vulnerable plaques from patients who died of AMI [acute
MI (myocardial infarction)] had greater inﬂammatory
macrophages and lymphocytes than stable plaques from
patients with SA (stable angina), which suggests that
activation of an immune response is involved in the
progression of ruptured and vulnerable plaques.
Currently ten TLRs (Toll-like receptors) have been
reported in mammalian species and these appear to
recognize distinct pathogen-associated molecular pat-
terns controlling innate immune responses [4]. Methe
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et al. [5] and our previous study [6] have demonstrated
that activation of TLR4 in circulating monocytes is
related to the downstream release of inﬂammatory cy-
tokines in patients with AMI. These studies suggest a po-
tential pathophysiological link between TLR4 signalling
and the immune response in coronary atherosclerosis.
TLR4 has been shown to be required not only for the
bacterialendotoxin-inducedinﬂammatoryresponses,but
also for non-bacterial ligands, such as oxidative stress,
fattyacidsandHSP(heat-shockprotein)[7–9].TLR2and
TLR4 immunostaining is frequently co-localized with
NF-κB (nuclear factor κB), which is a common down-
stream pathway of TLR2 and TLR4 signals, in athero-
sclerotic plaques [10]. There is cross-talk between TLR2
and TLR4, through which TLR2 expression is regulated
by TLR4 expression [11,12]. It has been reported that
there is an increase in both TLR2 and TLR4 levels in PB-
MCs(peripheralbloodmononuclearcells)obtainedfrom
patients with coronary artery disease [13]. A histological
study has shown that TLR4 but not TLR2 is expressed in
macrophage-inﬁltrated coronary artery plaques obtained
at autopsy [14]; however, it has not been determined
whether TLR2 and TLR4 are expressed at the site of the
culprit coronary artery in patients with AMI. The aim of
the present study was to determine whether TLR2 and




The present study included 62 consecutive patients with
ﬁrstQ-waveAMIundergoingPCI(percutaneouscoron-
ary intervention) and stenting with aspiration catheteriz-
ation, 20 patients with SA and 34 subjects with normal
coronary angiographic ﬁndings. Inclusion criteria for
AMI in the study were (i) continuous chest pain lasting
>30 min, (ii) arrival at our hospital within 12 h of the
onset of chest pain, (iii) ST-segment elevation 0.1 mV
in two or more contiguous leads on 12-lead ECG, and
(iv)anangiographicallydetectedculpritlesionwithTIMI
(thrombolysis in MI) ﬂow grade 2. In all patients with
AMI, myocardial damage was conﬁrmed by a troponin
T level above the upper limit of normal (0.1 μg/ml), and
a 2-fold increase in the creatinine kinase-MB isoenzyme.
Exclusion criteria were (i) a culprit lesion in the left
main coronary artery, (ii) a history of prior AMI, or (iii)
cardiogenic shock, heart failure or infectious illness at
the time of PCI. SA was diagnosed on the basis of the
presence of (i) a history of typical chest pain on effort,
(ii) lasting unchanged for more than 3 months and not
associated with rest angina, (iii) documenting exercise-
induced myocardial ischaemia, (iv) angiographically
proven coronary artery disease, and (v) the exclusion
parameters described for AMI. Controls were obtained
from 34 subjects with suspected SA on the basis of
symptoms and/or minor ECG changes. The resulting
coronary angiographic ﬁnding and close clinical
examination failed to show any evidence of SA, and these
subjects were thus designated as controls.
The study protocol was approved by our hospital
Ethics Committee, and informed consent was obtained
from all subjects.
Sampling of blood and plaque material
Systemic blood samples were taken ﬁrst from the
aortic arch prior to PCI. Local samples at the site of
occlusion were immediately obtained using aspiration
catheterization (TVAC; Nipro) after crossing the
occlusive lesion. Solid plaque materials were separated
from liquid blood using a microﬁlter (pore ﬁlter size
40 μm). Liquid blood samples were used for monocyte
isolation as local blood samples. Solid plaque material
was also used for immunohistochemistry. In patients
withSAandcontrols,systemicbloodsamplesweretaken
from the aortic arch at the time of coronary angiography.
Cell preparation
PBMCs were isolated from local and systemic blood
samples obtained from all subjects by Ficoll-Paque dens-
ity gradient centrifugation and lymphocyte separation
solution (Nacalai Tesque). To exclude platelet contamin-
ation, isolated PBMCs were washed and centrifuged
twice with PBS containing 5 mmol/l EDTA at 400 g
for 15 min at 20◦C [15]. Monocytes were isolated from
PBMCs by adherence to a plastic dish (120 min, 37◦C).
Monocytesweredetachedfromtheplasticdishbyincub-
ation in ice-cold PBS, washed three times with PBS and
then resuspended at a ﬁnal concentration of 1×106 cells/
ml in RPMI 1640 (Sigma–Aldrich).
Real-time RT (reverse transcription)-PCR
Total RNA was extracted from isolated monocytes by
the acid guanidinium thiocyanate/phenol chloroform
method [16] and were treated with DNase I (Gibco).
The published sequences for human TLR2 (for-
ward primer, 5 -GCCAGGCGGCTGCTC-3 ; reverse
primer, 5 -TTGCAACACCAAACACTGGG-3 ;a n d
TaqMan probe, 5 -CGTTCTCTCAGGTGACTGCT-
CGGAGTTC-3 ) [17] and TLR4 (forward primer, 5 -
TGATTGTTGTGGTGTCCCA-3 ; reverse primer,
5 -TGTCCTCCCACTCCAGGTAA-3 ; and TaqMan
probe, 5 -TCCTGCAGAAGGTGGAGAAGACCCT-
3 ) [18] were used for construction of primers and
TaqMan probe. mRNA of the housekeeping gene
GAPDH (glyceraldehyde-3-phosphate dehydrogenase)
was ampliﬁed using TaqMan GAPDH control reagents
as an internal control (PE Biosystems).
cDNA was synthesized and ampliﬁed from 100 ng of
total RNA and 10-fold serial dilutions of human control
RNA (PE Biosystem) by RT-PCR using a TaqMan EZ
RT-PCR kit (PE Biosystem). The cDNA products were
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synthesized at 60◦C for 30 min and ampliﬁed with 40
cyclesofPCR,witheachcycleconsistingofdenaturation
at 94◦C for 20 s, and annealing and extension at 62◦Cf o r
1 min. A quantitative PCR method was developed using
a 5-nuclease assay with detection on an ABI PRISM 7700
sequence detector (PE Biosystems). Ampliﬁcations were
performed three times for each RNA sample. Each PCR
run also included triplicate wells of each RNA sample.
Theratio between the copynumbers ofTLR2,TLR4and
GAPDH represented the normalized TLR2 and TLR4
levels for each sample and could be compared with those
of other samples. To account for PCR ampliﬁcation of
contaminating genomic DNA, a control without RT was
included.
Flow cytometric analysis
The amount of TLR2, TLR4 and CD14 on the monocyte
cell surface was measured by FACS. Isolated mono-
cytes were incubated with FITC-conjugated mouse anti-
(human TLR2) and (human TLR4) antibodies (Santa
CruzBiotechnology)andaPerCP(peridininchlorophyll
protein)-conjugatedCD14antibody(BectonDickinson).
Isotype-matched irrelevant control IgG was used as a
control (Becton Dickinson). TLR2 and TLR4 levels in
CD14-positive cells were measured using a FACScan
ﬂow cytometer (Becton Dickinson) and are shown as
MFIs (mean ﬂuorescence intensities).
Immunohistochemistry
A monoclonal antibody to TLR2 (1:100 dilution;
Apotech Biochem), a mouse monoclonal IgG2a against
humanTLR4(1:100dilution;SantaCruzBiotechnology)
and a monoclonal antibody to human CD68 (1:100
dilution; Dako) were used as primary antibodies. The
tissue sections were deparafﬁned with xylene for 20 min
and thoroughly dehydrated with serially diluted ethanol.
After inhibition of endogenous peroxidase and blocking
of non-speciﬁc reactions, primary antibodies were
applied. Biotinylated mouse Ig was used as a secondary
antibody. Peroxidase-labelled streptavidin (Histoﬁne;
MAX-PO kit; Nichiren) was applied and visualized
using DAB (diaminobenzidine) as the chromogen. The
speciﬁcity of the immunohistochemistry was conﬁrmed
by substituting the primary antibodies with a mouse




isolated monocytes were cultured in two culture media
with and without HSP70 stimulation, which is a putative
monocyte TLR ligand [9]. Monocytes were resuspended
in either non-activating medium [RPMI 1640 with 10%
(v/v) heat-inactivated FCS (fetal calf serum; Gibco),
penicillin and streptomycin] or activating medium
[RPMI 1640 with 2 μg/ml HSP70 (NSP-555; Stressgen
Bioreagents), 10% (v/v) heat-inactivated FCS, penicillin
and streptomycin]. Cells were then incubated in sterile
polypropylene tubes (Becton Dickinson) for 24 h at
37◦Ci n5%C O 2. TLR2 and TLR4 MFIs were measured
using the method described above. Cultured supernatant
concentrations of TNF-α (tumour necrosis factor-α)
were measured using the Bio-Plex system, which
combines the principle of a sandwich immunoassay with
Luminex ﬂuorescent-bead-based technology (sensitivity
0.25 pg/ml; Bio-Rad Laboratories) [19].
Clinical follow-up study
Follow-up coronary angiography was carried out as a
clinically driven event at least 6 months after PCI (mean
follow-up, 191+ −10 days) to determine the recurrence
of stenosis in all patients with AMI. Cardiac events
were deﬁned as target lesion revascularization (lesion
segment with 5 mm margins from each end), target vessel
revascularization (any intervention to the treated vessel),
cardiac death and recurrent Q-wave MI.
Statistical analysis
Continuous variables are presented as means+ −S.D.
Comparison of continuous variables was carried out
using Student’s t test and the non-parametric Mann–
Whitney test. Statistical analysis of categorical variables
was also carried out using χ2 analysis and Fisher exact
analysis. A value of P<0.05 was considered statistically
signiﬁcant.
RESULTS
Baseline and clinical characteristics
Baseline characteristics of patients with AMI, patients
with SA and controls are shown in Table 1.
Angiographic ﬁndings after PCI with
thrombus aspiration
All patients with AMI underwent stent implantation
using a bare metal stent (Driver® coronary stent system;
Medtronic).Liquidbloodsamplesintheculpritcoronary
artery were obtained from all patients with AMI. Solid
plaque materials were also obtained from 24 patients
with AMI. For the ﬁnal TIMI grade, the rate of TIMI3
was 85% in patients with AMI (Table 1).
Levels of TLR2 and TLR4
There was no difference in average CT (threshold cycle)
of GAPDH between the AMI, SA and control groups
(average CT of GAPDH, 20.76+ −1.73, 20.99+ −1.58
and 20.86+ −1.48 respectively; P=not signiﬁcant).
Spontaneous mRNA and protein (MFI) levels of TLR2
and TLR4 in systemic samples obtained from patients
with AMI were higher than in patients with SA and
controls (all P<0.01) (Figures 1 and 2). In patients with
AMI, local levels of TLR4 were higher than in systemic
samples (Figure 1), whereas there was no signiﬁcant
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Table 1 Baseline and clinical characteristics of study populations
Values are means+ −S.D., or numbers (percentage). ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin II type 1 receptor blockers; BMI, body mass index;
CAD, coronary artery disease; DBP, diastolic blood pressure; HbA1c glycated haemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; IFG, impaired
fasting glucose; IGT, impaired glucose tolerance; SBP, systolic blood pressure. ∗P <0.05 compared with patients with AMI.
Characteristic Patients with AMI Patients with SA Controls
n 62 20 34
Age (years) 64.0+ −13.4 64.6+ −12.2 62.1+ −10.1
Male gender (n) 44 (71%) 15 (75%) 27 (79%)
BMI (kg/m2) 24.7+ −3.0 23.9+ −4.6 23.1+ −4.7
Risk factors (n)
Hypertension 46 (74%) 15 (75%) 27 (79%)
Hypercholesterolaemia 41 (66%) 13 (65%) 23 (68%)
Diabetes or IGT/IFG 37 (60%) 11 (55%) 20 (59%)
Smoking 24 (39%) 7 (35%) 12 (35%)
Obesity 27 (44%) 8 (40%) 15 (44%)
SBP (mmHg) 127+ −15 25+ −18 24+ −11
DBP (mmHg) 71+ −11 72+ −14 69+ −13
HDL-cholesterol (mg/dl) 56+ −14 57+ −18 58+ −19
LDL-cholesterol (mg/dl) 111+ −30 109+ −39 107+ −41
HbA1c (%) 5.9+ −1.3 5.7+ −1.1 5.8+ −1.2
Angiographic degree of CAD (n)
One-vessel disease 37 (60%) 13 (65%) −
Two-vessel disease 18 (29%) 7 (35%) −
Three-vessel disease 7 (11%) 0 −
Culprit vessel (n) −
Left anterior descending artery 30 (48%) 10 (50%) −
Left circumﬂex artery 8 (13%) 3 (15%) −
Right coronary artery 24 (39%) 7 (35%) −
Medication (n) −
Aspirin 62 (100%) 19 (95%) 0∗
Nitrates 17 (27%) 10 (50%) 0∗
β-Blocker 15 (24%) 6 (30%) 5 (15%)
ACEI or ARB 36 (58%) 13 (65%) 19 (56%)
Statins 46 (74%) 12 (60%) 21 (62%)
Initial TIMI ﬂow grade (n)
05 2 ( 8 4 % ) 0 ∗ −
1 10 (16%) 2 (10%) −
20 1 8 ( 9 0 % ) ∗ −
30 0 −
Final TIMI ﬂow grade (n)
00 −−
10 −−
29 ( 1 5 % ) −−
35 1 ( 8 5 % ) −−
difference between local and systemic samples for TLR2
levels (Figure 2).
Immunohistochemistry for TLR2 and TLR4
Insolidplaquematerial removedfromthesiteoftherup-
tured plaque, staining for TLR4 was localized in inﬁltrat-
ing macrophages (Figure 3A) and was positive in all solid
plaque samples. Immunostaining of thrombus material
showed CD68-positive macrophages (Figure 3B). TLR2
stainingwasnotpresentinanyofthesamples(Figure3C).
There was no evidence of non-speciﬁc staining in solid
plaque material obtained from patients with AMI.
Changes in TLR2 and TLR4 levels in
response to HSP70
To quantify the effect of HSP70 stimulation on TLR
expression, TLR levels in HSP70-stimulated monocytes
were normalized to the corresponding levels in cultured
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Figure 1 TLR4 levels in local and systemic samples
(A) TLR4 mRNA and (B) TLR4 MFI. ∗P <0.05.
Figure 2 TLR2 levels in local and systemic samples
(A) TLR2 mRNA and (B) TLR2 MFI. ∗P <0.05 and ¶P >0.05.
monocytes without HSP70 stimulation, and levels were
expressed as fold changes. The fold changes in TLR2
and TLR4 levels with HSP70 stimulation were higher
in patients with AMI (both local and systemic samples)
compared with patients with SA and controls (Figure 4).
In patients with AMI, the fold change in TLR4 with
HSP70 stimulation was signiﬁcantly higher in local
samples than in systemic samples (Figure 4A), whereas
there was no signiﬁcant difference between local and
systemicsamplesforTLR2(Figure4B).Thefoldchanges
in supernatant TNF-α with HSP70 stimulation were
higher in patients with AMI than in patients with SA
and controls (Figure 4C). In patients with AMI, the
fold change in supernatant TNF-α levels with HSP70
stimulation was signiﬁcantly higher in local samples than
in systemic samples (Figure 4C).
Relationship between cardiac events and
TLR2 and TLR4 levels
At the time of the 6-month follow-up study, cardiac
events were observed in 16 out of 62 patients with AMI.
These events consisted of target lesion revascularization
in six patients, target vessel revascularization in seven
patients, recurrent MI in two patients and cardiac death
in one patient. When patients with AMI were divided
into two subgroups, according to the presence or absence
of cardiac events, both local and systemic levels of TLR4
were higher in patients with cardiac events than in those
without [local TLR4 mRNA, 4.32+ −1.24 compared with
2.05+ −0.64 respectively (P<0.01); local TLR4 MFI,
8.33+ −2.01 compared with 5.14+ −0.78 respectively
(P<0.01); systemic TLR4 mRNA, 2.67+ −0.89 compared
with 1.41+ −0.47 respectively (P<0.01); and systemic
TLR4 MFI, 4.99+ −1.50 compared with 4.23+ −1.19
Figure 3 Immunohistochemistry for TLR2, TLR4 and CD68 in thrombus samples obtained from patients with AMI
(A) Immunostaining for TLR4 (brown staining, arrows) in inﬁltrating macrophages (magniﬁcation, ×200). (B) CD68-positive macrophages (brown staining, arrows)
(magniﬁcation, ×200). (C) Immunostaining for TLR2 in thrombus samples obtained from patients with AMI (magniﬁcation, ×200).
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Figure 4 Cultured monocytes stimulated with HSP70
Fold change in TLR4 MFI (A), TLR2 MFI (B) and supernatant TNF-α levels
(C) with HSP70 stimulation. ∗P <0.01, ∗∗P <0.05 and ¶P >0.05.
respectively (P=0.03)]. In contrast, there were no signi-
ﬁcant differences in TLR2 levels between patients with
cardiac events than those without [local TLR2 mRNA,
1.39+ −0.48 compared with 1.47+ −0.48 (P=0.58); local
TLR2 MFI, 1.54+ −0.40 compared with 1.40+ −0.31
(P=0.20); systemic TLR2 mRNA, 1.52+ −0.61 compared
with 1.36+ −0.50 (P=0.24); and systemic TLR2 MFI,
1.58+ −0.47 compared with 1.36+ −0.44 (P=0.26)].
DISCUSSION
The major ﬁndings of the present study are: (i) in patients
withAMI,monocytelevelsofTLR4,butnotTLR2,were
higher in local samples surrounding ruptured plaques
than in systemic samples; (ii) TLR4 immunostaining
was observed in inﬁltrating macrophages in ruptured
plaque material, but TLR2 immunostaining was not;
(iii) the in vitro study suggests that HSP70-stimulated
levels of TLR4 in local samples were higher than in
systemic samples; and (iv) local and systemic levels of
TLR4 were higher in patients with AMI with cardiac
events than in those without.
It has become evident that atherosclerosis is an inﬂam-
matory disease involving an immune response during
its initiation and progression [20]. Studies have demon-
strated that the TLR signalling pathway is activated by
endogenous ligands, such as oxidative stress, fatty acids
and HSPs [7–9]. Epidemiological studies also suggested
that oxidative stress increases in subjects with many risk
factors for atherosclerosis, such as diabetes, hypertension
and smoking [21]. Some reports have demonstrated that
expression of TLR4 was mainly localized in inﬁltrating
macrophagesinatheroscleroticlesions,suggestingaclose
link between the progression of coronary atherosclerosis
and TLR4 signalling [10,14]. The present study has
shown that mRNA and protein levels of TLR2 and
TLR4 in circulating monocytes were higher in patients
with AMI prior to PCI than in patients with SA and
controls. Furthermore, in patients with AMI, the local
levels of TLR4 at the site of ruptured plaque were higher
than systemic levels. In agreement with the concept of
an increase in local TLR4 expression, immunostaining
demonstrated the localization of TLR4 in inﬁltrating
macrophages in ruptured plaque material occluding the
culprit coronary artery. The increase in local TLR4
levels in the culprit coronary artery in patients with
AMI is a novel and unexpected ﬁnding. An apoE
(apolipoprotien E)-deﬁcient mouse model has reported
that a loss of TLR4 and its adaptor molecule MyD88
(myeloid differentiation factor 88) decreased the severity
of atherosclerosis and altered atherosclerotic plaque
formation [22]. Furthermore, Bjorkbacka et al. [23]
demonstrated, using MyD88-null mice, that TLR4
deﬁciency was associated with alterations in coronary
plaque composition, which decreased both lipid and
macrophage content and markedly decreased the expres-
sion of pro-inﬂammatory factors, including pro-inﬂam-
matory cytokines and chemokines. An experimental
model has shown that activated macrophages within
plaques are capable of degrading the extracellular matrix
by secretion of MMP 9 (matrix metalloproteinase 9),
which can be stimulated by TLR4 activation and which
induces plaque degradation and rupture [24,25]. It has
alsobeenreportedthatactivatedTLR4signallinginduces
the expression of apoptotic molecules of the Fas death
pathway [26]. From these observations, it has been
suggestedthattheexpressionofTLR4ininﬁltratingmac-
rophages in coronary arteries may be an important factor
underlying coronary plaque destabilization and rupture.
In the present study, TLR2 levels did not differ
between local and systemic samples in patients with
AMI. Immunohistochemical ﬁndings showed that TLR2
immunostaining was not present in any plaque samples.
This suggests that circulating monocytes may be a major
cellular source of TLR2 expression in patients with AMI.
We have shown that TLR2 and TLR4 levels in circu-
lating monocytes were higher in patients with AMI than
inpatientswithSAandcontrols.Ourpreviousstudy[27]
demonstrated that circulating monocytes release HSP70,
which is a potent endogenous ligand of monocyte TLR4
signalling, in response to myocardial ischaemic damage.
Aseaetal.[28]havereportedthatthereleaseofHSP70,as
a common endogenous ligand of both TLR2 and TLR4,
inresponsetoischaemicmyocardiummayactivateTLR2
and TLR4 signalling in circulating monocytes. TLR4 sig-
nalling up-regulates TLR2 in LPS (lipopolysaccharide)-
stimulated macrophages, suggesting that the cross-talk




Our in vitro study has shown that recombinant HSP70
didindeedinducetheexpressionofbothTLR4andTLR2
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and the downstream release of TNF-α from monocytes.
The increase in the levels of these molecules was greater
inpatientswithAMIthaninpatientswithSAorcontrols.
TheseﬁndingsindicatethatbothTLR2andTLR4signals
in monocytes may be up-regulated in patients with AMI
compared with patients with SA and controls. It is
thereforespeculatedthatthemonocyteTLR4signalinthe
responsetoischaemicmyocardialinjurymaymediatethe
TLR2 signal via a positive feedback loop and be involved
in the activation of the immune response in patients with
AMI.
An important ﬁnding of our 6-month follow-up
study was that systemic and local levels of TLR4 were
higher in patients with AMI with cardiac events than
in those without. TLR4 is associated with the initiation
of an inﬂammatory response and production of chemo-
kines and cytokines [30,31]. Increased pro-inﬂammatory
cytokines, in particular TNF family members, have been
shown to predict long-term incidence of adverse cardio-
vascular events in patients with AMI [32]. Although
the present study could not conﬁrm whether the local
TLR signal affects the systemic TLR4 signal, monoyctic
activation of both systemic and local TLR4 signals may
be associated with the incidence of cardiac events in
patients with AMI. A mouse model of MI has recently
shown that inhibition of TLR4 with its antagonist
attenuates the inﬂammatory response to MI, as shown
by a signiﬁcant decrease in infarct size and expression
of inﬂammatory mediators [33]. It has been reported
that a new benzisothiazole derivative, which inhibits
TLR4 signal transduction, suppressed LPS-induced
up-regulation of cytokines, adhesion molecules and pro-
coagulant activity in human vascular endothelial cells
and peripheral mononuclear cells, suggesting that this
compound may inhibit the progression of atherosclerosis
[34]. TLR4 signalling may therefore represent a signi-
ﬁcant target molecule for the design of speciﬁc inhibitors
as a novel therapeutic agent to AMI.
A limitation of the present study is the small number
ofpatientswithAMIwithrecurrentMIandcardiacdeath
compared with those with coronary revascularization in
the follow-up study. This may be due to the exclusion
from the study of patients with severe AMI, such as a
culpritlesion in the leftmain coronaryartery, a historyof
prior MI, cardiogenic shock or heart failure. In addition,
the present study was limited by a small number of sub-
jectsandalackoftime-coursedatarelatingtoTLRlevels.
Further studies will therefore be needed to establish
a causal relationship between TLR4 levels and cardiac
events in patients with AMI.
The results of the present study indicate an increase
in monocytic TLR4 expression not only in the systemic
circulation, but also at the site of plaque rupture. In
conclusion, expression of both systemic and local plaque
TLR4 may be one of the mechanisms responsible for the
pathogenesis of AMI.
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